

Przemysław Juszczyński

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1060159/publications.pdf>

Version: 2024-02-01

107
papers

4,187
citations

257357

24
h-index

114418

63
g-index

113
all docs

113
docs citations

113
times ranked

6465
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent imbalance, anti-apoptotic, and anti-inflammatory signature of circulating C-C chemokines and cytokines in patients with paroxysmal nocturnal hemoglobinuria. <i>Cytokine</i> , 2022, 150, 155780.	1.4	0
2	Super enhancers as master gene regulators in the pathogenesis of hematologic malignancies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188697.	3.3	8
3	Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. <i>European Journal of Haematology</i> , 2021, 106, 320-326.	1.1	2
4	PIM Kinases Promote Survival and Immune Escape in Primary Mediastinal Large B-Cell Lymphoma through Modulation of JAK-STAT and NF- κ B Activity. <i>American Journal of Pathology</i> , 2021, 191, 567-574.	1.9	16
5	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. <i>Scientific Reports</i> , 2021, 11, 10017.	1.6	3
6	The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2683.	1.0	4
7	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. <i>Cancer Research</i> , 2021, 81, 6029-6043.	0.4	20
8	RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation. <i>Blood</i> , 2021, 138, 1518-1518.	0.6	0
9	Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML. <i>Blood</i> , 2021, 138, 2371-2371.	0.6	0
10	DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells. <i>Experimental Hematology</i> , 2020, 88, 56-67.e2.	0.2	7
11	SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. <i>Cell Death and Disease</i> , 2020, 11, 956.	2.7	20
12	Rebelle epigenome: histone H3S10 phosphorylation and H3S10 kinases in cancer biology and therapy. <i>Clinical Epigenetics</i> , 2020, 12, 147.	1.8	49
13	Serine Biosynthesis Pathway Supports MYC-miR-494-EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells. <i>Cancers</i> , 2020, 12, 580.	1.7	33
14	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. <i>Haematologica</i> , 2020, 105, 1361-1368.	1.7	23
15	BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells. <i>Molecular Oncology</i> , 2020, 14, 1817-1832.	2.1	12
16	Abstract 6217: Synergistic effect of CDK8 and BCL-2 inhibition in AML through regulation of MCL-1 and BIM balance. , 2020, , .		0
17	PIM Kinase Inhibition Decreases the Proangiogenic Properties of Multiple Myeloma Cells and Affects the Metabolic State of the Vascular Endothelium. <i>Blood</i> , 2020, 136, 16-17.	0.6	1
18	SIRT1 and HSP90alpha Are Functionally Linked and Control Mitotic Chromosome Segregation and Cell Viability in a Subset of Dlbcls. <i>Blood</i> , 2020, 136, 28-29.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Hodgkin Lymphoma Reed-Sternberg Cells Induce Immunosuppressive and Pro-Angiogenic Phenotype of Tumor-Associated Macrophages in a Paracrine Manner. <i>Blood</i> , 2020, 136, 30-30.	0.6	0
20	Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. <i>Blood</i> , 2020, 136, 33-34.	0.6	0
21	Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia. <i>Molecular Oncology</i> , 2019, 13, 1180-1195.	2.1	24
22	Abstract 1306: SEL120, a potent and specific inhibitor of CDK8 induces complete remission in human patient derived xenograft models of acute myeloid leukemia. , 2019, , .		1
23	Predictive Significance of Selected Gene Mutations Identified Using Next Generation Sequencing in Relapsed and Refractory Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib. <i>Blood</i> , 2019, 134, 5456-5456.	0.6	0
24	CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation. <i>Blood</i> , 2019, 134, 3774-3774.	0.6	0
25	SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial. <i>Blood</i> , 2019, 134, 2651-2651.	0.6	2
26	Mechanizmy działania i strategie oporności komórek nowotworowych przeciwko apoptozie indukowanej przez TRAIL. <i>Hematologia</i> , 2019, 10, 135-147.	0.0	0
27	Perspektywy rozwoju strategii terapeutycznych opartych na TRAIL i jego analogach w hematologii. <i>Hematologia</i> , 2019, 10, 148-160.	0.0	0
28	Microenvironment-induced PIM kinases promote CXCR 4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3548-3559.	1.6	17
29	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. <i>Oncolmmunology</i> , 2018, 7, e1423183.	2.1	23
30	BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation. <i>Annals of Oncology</i> , 2018, 29, viii463-viii464.	0.6	3
31	An immunomagnetic cell separation system based on a retroviral vector containing a chimeric, recombinant human-murine CD4 gene. <i>Central-European Journal of Immunology</i> , 2018, 43, 353-357.	0.4	1
32	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 16917-16931.	0.8	25
33	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. <i>Haematologica</i> , 2018, 103, 1843-1852.	1.7	8
34	Abstract B17: FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies. , 2018, , .		0
35	CDK8 Inhibitor SEL120-34A Has Therapeutic Efficacy in Murine and Human Acute Myeloid Leukemia Models. <i>Blood</i> , 2018, 132, 1520-1520.	0.6	0
36	New insights into redox homeostasis as a therapeutic target in B-cell malignancies. <i>Current Opinion in Hematology</i> , 2017, 24, 393-401.	1.2	24

#	ARTICLE	IF	CITATIONS
37	Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 1418-1429.	0.6	42
38	MiR-17-92 represses PTPROT and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells. <i>Experimental Hematology</i> , 2017, 46, 56-61.e1.	0.2	13
39	Instytut Hematologii i Transfuzjologii "nowatorskie rozwiązania polegające na kompleksowości, koordynacji, innowacyjności i jakości w celu poprawy diagnostyki i leczenia, komfortu chorego i postępu w medycynie. <i>Hematologia</i> , 2017, 7, 173-216.	0.0	0
40	Molekularna patogeneza przewlekłej białaczki limfocytowej. <i>Hematologia</i> , 2017, 7, 273-286.	0.0	1
41	Abstract 4087: Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of hematological malignancies. , 2017, , .		0
42	Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients. <i>European Journal of Haematology</i> , 2016, 96, 181-187.	1.1	14
43	FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. <i>Oncogene</i> , 2016, 35, 5989-6000.	2.6	42
44	FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. <i>Blood</i> , 2016, 127, 739-748.	0.6	54
45	Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease. <i>Leukemia and Lymphoma</i> , 2016, 57, 1471-1473.	0.6	1
46	Microenvironment-Induced Expression of PIM Kinases Supports Chronic Lymphocytic Leukemia Cells Survival and Promotes CXCR4-mTOR Pathway Dependent Migration. <i>Blood</i> , 2016, 128, 3239-3239.	0.6	4
47	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893.	1.1	26
48	Rodzina onkogennych kinaz PIM "potencjalne cele terapeutyczne w nowotworach układu krwiotwórczego i chłonnego. <i>Nowotwory</i> , 2016, 66, 1-11.	0.1	0
49	Functional Link Between Heat Shock Protein HSP90alpha and Sirtuin 1 (SIRT1) in the Pathogenesis of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2016, 128, 4120-4120.	0.6	0
50	Downregulation of Deptor By MiR-155 Promotes Cell Survival through Activation of PI3K/AKT and NFkB Signaling in ABC-Type Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 1761-1761.	0.6	2
51	Promoter DNA methylation and expression levels of HOXA4, HOXA5 and MEIS1 in acute myeloid leukemia. <i>Molecular Medicine Reports</i> , 2015, 11, 3948-3954.	1.1	18
52	MiR-155 Amplifies AKT and NFkB Signaling By Targeting Multiple Regulators of BCR Signal in DLBCL. <i>Blood</i> , 2015, 126, 2455-2455.	0.6	6
53	FOXO1-p300-Txn Circuit Regulates Oxidative Stress Responses in Diffuse Large B-Cell Lymphomas Characterized By Enhanced Oxidative Phosphorylation. <i>Blood</i> , 2015, 126, 466-466.	0.6	1
54	A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity. <i>Blood</i> , 2015, 126, 706-706.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Nowe cele terapii ukierunkowanej w nowotworach układu chłonnego z perspektywy ostatnich 5 lat badań. Hematologia, 2015, 6, 1-9.	0.0	1
56	Abstract 5394: First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies. Cancer Research, 2015, 75, 5394-5394.	0.4	1
57	HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications. Blood, 2015, 126, 1436-1436.	0.6	0
58	FOXO1 Activation Is an Effector of SYK and AKT Inhibition in Tonic BCR Signal-Dependent Diffuse Large B-Cell Lymphomas. Blood, 2015, 126, 314-314.	0.6	0
59	Activity of PIM Kinases in Chronic Lymphocytic Leukemia Modulates Tumor Cell Survival and Stromal Interactions through a Pleiotropic Mechanism Involving Modulation of CXCR4 - mTOR Pathway. Blood, 2015, 126, 1549-1549.	0.6	0
60	Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma. Blood, 2015, 126, 819-819.	0.6	0
61	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. Blood, 2015, 126, 4917-4917.	0.6	0
62	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. MAbs, 2014, 6, 1300-1313.	2.6	16
63	Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients. Leukemia Research, 2014, 38, 850-856.	0.4	16
64	MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 457-467.	3.3	42
65	FOXO1 Transcription Factor: A Critical Effector of the PI3K-AKT Axis in B-Cell Development. International Reviews of Immunology, 2014, 33, 146-157.	1.5	63
66	Repetitive genomic elements and overall DNA methylation changes in acute myeloid and childhood B-cell lymphoblastic leukemia patients. International Journal of Hematology, 2014, 100, 79-87.	0.7	17
67	Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies. Cancer Research, 2014, 74, 1749-1749.	0.4	2
68	Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients. Experimental Hematology, 2013, 41, S27.	0.2	0
69	SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas. Cancer Cell, 2013, 23, 826-838.	7.7	152
70	CXCR4 Upregulation Is a Biomarker Of Sensitivity To Targeted Inhibition Of B-Cell Receptor Signaling In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 631-631.	0.6	1
71	Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy. Clinical Cancer Research, 2012, 18, 1611-1618.	3.2	582
72	Correction: Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy: Figure 3.. Clinical Cancer Research, 2012, 18, 2117-2117.	3.2	1

#	ARTICLE	IF	CITATIONS
73	Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1824-1827.	0.6	9
74	Molecular Pathogenesis of Aggressive B-cell Lymphomas. <i>Principles and Practice</i> , 2012, , 55-70.	0.3	0
75	Gene Expression Profiling in Hematologic Malignancies. <i>Principles and Practice</i> , 2012, , 199-214.	0.3	0
76	Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. <i>Blood</i> , 2011, 117, 4315-4322.	0.6	75
77	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2010, 116, 3268-3277.	0.6	1,122
78	MLL-Rearranged B Lymphoblastic Leukemias Selectively Express the Immunoregulatory Carbohydrate-Binding Protein Galectin-1. <i>Clinical Cancer Research</i> , 2010, 16, 2122-2130.	3.2	39
79	The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , 2009, 144, 358-366.	1.2	30
80	BBAP Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response. <i>Molecular Cell</i> , 2009, 36, 110-120.	4.5	133
81	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. <i>Blood</i> , 2009, 114, 5315-5321.	0.6	53
82	The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma. <i>Current Immunology Reviews</i> , 2009, 5, 300-310.	1.2	3
83	The BBAP E3 Ligase Monoubiquitylates Histone H4 at Lysine 91 and Selectively Modulates the DNA Damage Response in Chemotherapy-Resistant Lymphomas.. <i>Blood</i> , 2009, 114, 3958-3958.	0.6	1
84	Expression and Targeted Inhibition of the Immunoregulatory Carbohydrate-Binding Lectin, Galectin 1, in EBV-Driven Post-Transplant Lymphoproliferative Disorders.. <i>Blood</i> , 2009, 114, 96-96.	0.6	0
85	Host immune response in B-cell lymphomas: friend or foe?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2008, 56, 245-255.	1.0	8
86	AP1-Dependent Galectin-1 Expression Delineates Classical Hodgkin and Anaplastic Large Cell Lymphomas from Other Lymphoid Malignancies with Shared Molecular Features. <i>Clinical Cancer Research</i> , 2008, 14, 3338-3344.	3.2	67
87	SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. <i>Blood</i> , 2008, 111, 2230-2237.	0.6	289
88	Selective Expression of the Immunoregulatory Lectin, Galectin-1, in Precursor B Cell Acute Lymphoblastic Leukemias (ALLs) with MLL Rearrangements. <i>Blood</i> , 2008, 112, 2539-2539.	0.6	18
89	BCL6 Regulates Tonic BCR Signaling in Diffuse Large B-Cell Lymphomas by Repressing the SYK Phosphatase, PTPROt. <i>Blood</i> , 2008, 112, 802-802.	0.6	0
90	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3207-3212.	3.3	130

#	ARTICLE	IF	CITATIONS
91	The AP1-dependent secretion of galectin-1 by Reedâ€™Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13134-13139.	3.3	299
92	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood, 2007, 110, 2067-2074.	0.6	117
93	Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia. Haematologica, 2007, 92, 710-711.	1.7	12
94	Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Genes Chromosomes and Cancer, 2007, 46, 500-507.	1.5	23
95	Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkinâ€™s lymphoma outcome. Tissue Antigens, 2007, 71, 071029015950001-???	1.0	11
96	Protein tyrosine phosphatase receptorâ€™type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cellâ€™receptor signaling, and cellular proliferation. Blood, 2006, 108, 3428-3433.	0.6	86
97	BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate. Molecular and Cellular Biology, 2006, 26, 5348-5359.	1.1	107
98	BCL6 Programs Lymphoma Cells for Survival and Differentiation through Distinct Biochemical Mechanisms, Both of Which Can Be Therapeutically Targeted.. Blood, 2006, 108, 225-225.	0.6	1
99	Tonic B-Cell Receptor Signaling Promotes the Survival of Diffuse Large B-Cell Lymphomas: Identification of SYK as a Rational Treatment Target.. Blood, 2006, 108, 226-226.	0.6	6
100	Hodgkinâ€™s Lymphoma Reed Sternberg Cells over Express the T-Cell Inhibitory Carbohydrate-Binding Lectin, Galectin 1: Role of AP-1 and Likely Mechanism of Tumor Immune Escape.. Blood, 2006, 108, 469-469.	0.6	1
101	Protein Tyrosine Phosphatase Receptor-Type O Truncated (PTPROT) Regulates SYK Phosphorylation, Proximal B-Cell Receptor Signaling and Cellular Proliferation.. Blood, 2006, 108, 933-933.	0.6	0
102	Heat Shock Protein 90 (HSP90) Is a Rational Therapeutic Target in Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 829-829.	0.6	0
103	A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 616-616.	0.6	0
104	B-Aggressive Lymphoma Gene (BAL) Is a Risk-Related, Î³IFN-Inducible Gene That Is Expressed in Primary Diffuse Large B-Cell Lymphomas with a Brisk Host Inflammatory Response.. Blood, 2004, 104, 2035-2035.	0.6	5
105	Expression of the Multidrug Resistance-associated Protein (mrp) Gene in Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 2002, 43, 153-158.	0.6	10
106	Comparison Study for Genotyping of a Single-Nucleotide Polymorphism in the Tumor Necrosis Factor Promoter Gene. Diagnostic Molecular Pathology, 2002, 11, 228-233.	2.1	4
107	Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood, 2002, 100, 3037-3040.	0.6	78